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1. INTRODUCTION {#cam42638-sec-0005}
===============

Anemia is the major clinical concern for patients with myelodysplastic syndromes (MDS). It is present in about two of three patients at diagnosis, eventually rendering most of them transfusion dependent.[1](#cam42638-bib-0001){ref-type="ref"} Moreover, anemia is the main cause of both morbidity and mortality[2](#cam42638-bib-0002){ref-type="ref"} in MDS patients with a lower risk of progression according to the International Prognostic Scoring System (IPSS)[3](#cam42638-bib-0003){ref-type="ref"} and to its revised form (IPSS‐R).[4](#cam42638-bib-0004){ref-type="ref"}

Erythropoietic‐stimulating agents (ESAs), in particular recombinant human erythropoietin (rhEPO), have been used to overcome anemia in MDS patients since the last three decades, soon after it became available in clinics for the treatment of anemia due to renal failure.[5](#cam42638-bib-0005){ref-type="ref"} ESAs have been shown to improve the clinical outcome of anemic MDS patients, ameliorating their quality of life,[6](#cam42638-bib-0006){ref-type="ref"}, [7](#cam42638-bib-0007){ref-type="ref"} and possibly exerting a positive impact on survival in patients achieving a significant increase in hemoglobin (Hb) and/or a reduction of transfusion need.[8](#cam42638-bib-0008){ref-type="ref"}, [9](#cam42638-bib-0009){ref-type="ref"} In 2018 rhEPO has been approved by EMA for IPSS lower‐risk MDS with endogenous levels \<200 U/L and Hb \<10 g/dL.

Unfortunately, not all patients treated with ESAs respond. Early studies explored the effects of weight‐adjusted doses of rhEPO in MDS anemic patients. Using these doses, usually slightly inferior to 30‐40.000 IU weekly, an erythroid response was obtained in 15%‐25% of MDS patients.[10](#cam42638-bib-0010){ref-type="ref"} Although encouraging, these results were inferior to more recent ones reporting a response rate \>50%.[11](#cam42638-bib-0011){ref-type="ref"}, [12](#cam42638-bib-0012){ref-type="ref"} Higher response rate to ESAs currently observed is due to the better selection of MDS patients based on criteria developed and consolidated over the years.[9](#cam42638-bib-0009){ref-type="ref"} The use of doses of rhEPO higher than 40.000 IU is also deemed responsible for the improvement of response rates,[13](#cam42638-bib-0013){ref-type="ref"}, [14](#cam42638-bib-0014){ref-type="ref"}, [15](#cam42638-bib-0015){ref-type="ref"} and it has been recently recommended.[16](#cam42638-bib-0016){ref-type="ref"} The real clinical impact of higher vs lower doses of ESAs has never been evaluated in a randomized study or in a pair‐matched comparison, and we hypothesized that this type of analysis would clarify the role of different ESA doses in influencing response, overall survival, and progression to AML.

We thus retrospectively assessed the impact of higher vs lower doses of rhEPO on response to therapy and survival in two groups of MDS patients matched for clinical characteristics determining propensity to receive ESAs treatment. We limited this evaluation to rhEPO, given the scarce use of darbepoetin for MDS patients in Italy.

2. PATIENTS AND METHODS {#cam42638-sec-0006}
=======================

2.1. Patient selection and data collection {#cam42638-sec-0007}
------------------------------------------

This retrospective propensity‐matched cohort study was conducted using the Italian nation‐wide dataset of Fondazione Italiana Sindromi Mielodisplastiche (FISM‐Onlus), which includes more than 5000 MDS patients enrolled in the Italian Network of regional MDS registries (<https://ClinicalTrials.gov> Identifier: NCT02808858). The study was approved by the Ethics Committee and conducted according to national regulations for retrospective studies.

A cohort of MDS anemic patients treated with higher doses (HD) of rhEPO, defined as 40.000 IU twice a week, within 6 months from diagnosis was first identified. A second cohort, with a similar propensity to be treated with rhEPO according to clinical parameters known to influence the choice for a trial with ESAs[17](#cam42638-bib-0017){ref-type="ref"}, [18](#cam42638-bib-0018){ref-type="ref"} and treated with lower, "standard doses" (SD), defined as 40.000 IU weekly, was compared with the first one by using a 2:1 propensity score matching. Hematological improvement‐erythroid (HI‐E) was evaluated after 3 months of therapy, applying IWG 2006 criteria.[19](#cam42638-bib-0019){ref-type="ref"}

2.2. Statistical analysis {#cam42638-sec-0008}
-------------------------

Demographics and clinical characteristic of the patients were summarized as median (range) for continuous variables and number (%) for categorical variables. Relationships between categorical variables were examined by means of chi‐square test. Univariate analyses were performed to evaluate the response to therapy, progression to acute myeloid leukemia (AML), and prognostic impact on survival of individual and clinical variables. Overall survival (OS) was estimated using as survival time the difference (in months) between the date of death or last follow‐up and the date of start of therapy. Patients lost to follow‐up were censored at the date of their last visit. Kaplan‐Meier method was applied in univariate analysis to estimate survival probabilities and log‐rank test was carried out to assess heterogeneity within each prognostic factor. The cumulative 1‐, 2‐, and 3‐year survival probabilities were estimated.

To overcome mis‐estimating response to therapy and OS due to possible differences in patient baseline parameters between the two groups, a propensity score for each patient was calculated by a multivariable logistic regression analysis after allowance for age, MDS WHO 2008 classification, bone marrow blasts (\<5% vs ≥5%), endogenous EPO (\>200 vs ≤200 mU/mL), transfusion dependency (yes vs no), Hb (\>8 vs ≤8 g/dL), ferritin (\>350 vs ≤350 µg/L), and IPSS score (intermediate 1 or higher vs low). These variables were selected as relevant and conditioning predictors of rhEPO dose choice. The logistic regression coefficients of the variables that were significant in the model were then used to compute the propensity score.[20](#cam42638-bib-0020){ref-type="ref"} This score represents the probability that a patient would receive treatment with higher rhEPO doses based on variables which were suspected to influence group assignment. A 1:2 matched study group was created with the use of the nearest approach.

To estimate the effect of treatment dose on HI‐E and progression to AML in matched‐pair analysis, a multivariate analysis was performed by the random intercept logistic regression modeling for clustered data, adjusting for sex. The associated results are reported as odds ratio (OR) with 95% confidence intervals (CI). The effect of treatment doses and of sex on overall survival was estimated through the random intercept Cox regression modeling and the results are reported as hazard ratios (HR) with 95% CI.

A two‐tailed *P*‐value \<.05 was considered statistically significant. All analyses were performed using SPSS software v. 20 by IBM.

3. RESULTS {#cam42638-sec-0009}
==========

3.1. Characteristics of the study group of MDS patients {#cam42638-sec-0010}
-------------------------------------------------------

At the time of data lockup (31 December 2016), 445 anemic patients (104 treated with HD and 341 with SD) with complete clinical annotations in the FISM registry satisfied the eligibility criteria and entered the study. Baseline patient characteristics, before matching, are reported in Table [1](#cam42638-tbl-0001){ref-type="table"}.

###### 

Clinical characteristics of the patients at diagnosis. All patients (n = 445)

                                  Therapy         *P*              
  ------------------------------- --------------- ---------------- --------
  Total                           341 (76.6)      104 (23.4)        
  Sex                                                              \<.001
  Male                            179 (52.5)      77 (74.0)         
  Female                          162 (47.5)      27 (26.0)         
  Age median (range)              75 (39‐98)      75 (30‐96)        
  ≤75                             176 (51.6)      57 (54.8)        .58
  \>75                            165 (48.4)      47 (45.2)         
  WHO classification                                                
  RA                              132 (38.7)      30 (28.8)         
  RARS                            38 (11.1)       17 (16.5)         
  RCMD                            102 (29.9)      32 (31.1)         
  RAEB1                           33 (9.7)        15 (14.6)         
  RAEB2                           12 (3.5)        3 (2.9)           
  MDS with isolated 5q‐           20 (5.9)        4 (3.9)           
  MDS‐U                           4 (1.2)         2 (1.9)           
  Not available                   ---             1 (1.0)           
  Hemoglobin median (range)g/dL   9.1 (2‐12.8)    8.9 (5.1‐13.1)    
  ≤8                              74(21.7)        30(28.8)         .15
  \>8                             267(78.3)       74 (71.2)         
  [\<]{.ul}9                      203 (59.5)      64 (61.5)        .73
  \>9                             138 (40.5)      40 (38.5)         
  [\<]{.ul}10                     304 (89.1)      97 (93.3)        .26
  \>10                            37 (10.9)       7 (6.7)           
  Bone marrow blasts (%)                                           .55
  \<5                             287 (84.2)      85 (81.7)         
  ≥5                              54 (15.8)       19 (18.3)         
  Transfusion dependency                                           .60
  No                              259 (76.0)      76 (73.1)         
  Yes                             82 (24.0)       28 (26.9)         
  IPSS score risk                                                  .013
  Low                             205 (60.1)      46 (44.2)         
  Intermediate 1                  112 (32.8)      52 (50.0)         
  Intermediate 2                  22 (6.5)        6 (5.8)           
  High                            2 (0.6)         ---               
  IPSS‐R score risk                                                .26
  Very low                        74 (21.7)       22 (21.2)         
  Low                             162 (47.5)      39 (37.5)         
  Intermediate                    68 (19.9)       30 (28.8)         
  High                            27 (7.9)        8 (7.7)           
  Very high                       10 (2.9)        5 (4.8)           
  Ferritin median (range) μg/L    288 (4‐4985)    321.5 (6‐1600)    
  ≤350                            200 (58.7)      47 (45.2)        .018
  \>350                           141 (41.3)      57 (54.8)         
  EPO median (range) mU/mL        59.0 (2‐3420)   75 (1‐1700)       
  ≤200                            289 (84.8)      80 (76.9)        .074
  \>200                           52 (15.2)       24 (23.1)         
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3.2. Outcomes of the propensity score‐matched cohorts {#cam42638-sec-0011}
-----------------------------------------------------

All the 104 MDS patients treated with HD were matched with 208 patients treated with SD in a 1:2 fashion. Detailed characteristics of these two cohorts at the time of starting treatment are shown in Table [2](#cam42638-tbl-0002){ref-type="table"}. After matching, all covariates were well balanced, with nonsignificant difference in therapy‐related variables between the two cohorts.

###### 

Clinical characteristics of patients after propensity score matching (n = 312) at the start of rhEPO treatment

                                   Propensity score‐matched patients                
  -------------------------------- ----------------------------------- ------------ --------
  Total                            208 (66.7)                          104 (33.3)    
  Sex                                                                               \<.001
  Male                             106 (51.0)                          77 (74.0)     
  Female                           102 (49.0)                          27 (26.0)     
  Age median (range)                                                                1.0
  [\<]{.ul}75                      114 (55.1)                          57 (54.8)     
  \>75                             93 (44.9)                           47 (45.2)     
  WHO classification                                                                .90
  RA                               75 (36.1)                           30 (28.8)     
  RARS                             26 (12.5)                           17 (16.5)     
  RCMD                             60 (28.8)                           32 (31.1)     
  RAEB1                            27 (13.0)                           15 (14.6)     
  RAEB2                            5 (2.4)                             3 (2.9)       
  MDS with isolated 5q‐            11 (5.3)                            4 (3.9)       
  MDS‐U                            4 (1.9)                             2 (1.9)       
  Not available                    ---                                 1 (1.0)       
  Hemoglobin median (range) g/dL                                                     
  ≤8                               47(22.6)                            30(28.8)     .26
  \>8                              161(77.4)                           74(71.2)      
  \<9                              127 (61.1)                          64 (61.5)    1.0
  \>9                              81 (38.9)                           40 (38.5)     
  [\<]{.ul}10                      188 (90.4)                          97 (93.3)    .52
  \>10                             20 (9.6)                            7 (6.7)       
  Bone marrow blasts (%)                                                            1.0
  \<5                              169 (81.3)                          85 (81.7)     
  [\>]{.ul}5                       39 (18.8)                           19 (18.3)     
  Transfusion dependency                                                            .89
  No                               149(71.6)                           76 (73.1)     
  Yes                              59 (28.4)                           28 (26.9)     
  IPSS score risk                                                                   .44
  Low                              104 (50.0)                          46 (44.2)     
  Intermediate 1                   92 (44.2)                           52 (50.0)     
  Intermediate 2                   10 (4.8)                            6 (5.8)       
  High                             2 (1.0)                             ---           
  IPSS‐R score risk                                                                 .72
  Very low                         41 (19.7)                           22 (21.2)     
  Low                              91 (43.8)                           39 (37.5)     
  Intermediate                     51 (24.5)                           30 (28.8)     
  High                             19 (9.1)                            8 (7.7)       
  Very high                        6 (2.9)                             5 (4.8)       
  Ferritin median (range) μg/L                                                      1.0
  ≤350                             95 (45.7)                           47 (45.2)     
  \>350                            113 (54.3)                          57 (54.8)     
  EPO median (range) mU/mL                                                          .67
  ≤200                             165 (79.3)                          80 (76.9)     
  \>200                            43 (20.7)                           24 (23.1)     
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3.3. Achievement of HI‐E according to ESA doses {#cam42638-sec-0012}
-----------------------------------------------

Overall, HI‐E was observed in 164 matched patients (52.6%). Nonsignificant differences were observed with regard to rhEPO doses: HI‐E was obtained in 54.8% of patients with SD vs 48.1% with HD, respectively (*P* = .28).

At univariate analysis, a statistically significant higher HI‐E was observed in patients with transfusion independence (no vs yes, *P* \< .001), with an IPSS‐R lower‐risk score category (very low‐low vs intermediate‐very high, *P* \< .001), and with lower serum EPO concentration (≤200 vs \>200, *P* = .027). A trend to higher HI‐E was found in patients with \<5% of marrow blasts (*P* = .08). Fewer responses were observed in patients with del (5q) and RAEB2 (20% and 25%, respectively) which were significantly different to response rates observed in RA (with or without ringed sideroblasts, RARS) and RCMD cases (58. 8% and 47.6%, respectively, *P* = .04) (Table [S1](#cam42638-sup-0001){ref-type="supplementary-material"}). Multivariate analysis taking into consideration rhEPO doses, transfusion dependency, serum EPO levels, marrow blast percentage, WHO classification, and IPSS‐R, confirmed the predictive value of transfusion dependency (no vs yes: OR = 1.71, 95% CI 1.30‐2.25; *P* \< .001) and IPSS‐R (very low‐low vs higher risk: OR = 1.45, 95% CI 1.03‐2.06, *P* = .035) while patients with del (5q) were confirmed to have a lower response rate (OR: 0.23, 95% CI 0.07‐0.79, *P* = .020). rhEPO doses were not significantly correlated with HI‐E (*P* = .39) (Table [S2](#cam42638-sup-0001){ref-type="supplementary-material"}).

3.4. Overall survival according to ESA doses and response {#cam42638-sec-0013}
---------------------------------------------------------

Median OS was 64.6 months (95% CI 49.2‐79.9 months). After a median observation time of 44.2 months (range 1.6‐156.8) and 26.7 months (range 1.8‐114.6) for censored and deceased patients, respectively, 133 patients (42.6%: 44.2% in SD and 39.4% in HD cohorts, respectively) died. One‐, 2‐ and 3‐year survival probabilities were 80%, 66%, and 37%, respectively. A no significant trend to longer OS was observed for the HD vs SD cohort (80.2 months, 95% CI 31.1‐129.3 for HD vs 58.5 months, 95% CI 42.3‐74.7 for SD; *P* = .78; Figure [1](#cam42638-fig-0001){ref-type="fig"}).

![Overall survival of propensity score‐matched patients according to rhEPO doses](CAM4-8-7567-g001){#cam42638-fig-0001}

At univariate analysis, female gender (*P* = .010), younger age (≤75 year, *P* \< .001), low ferritin levels (≤350, *P* = .010), transfusion independence (*P* \< .001), lower marrow blast percentage (≤5%, *P* = .001), and IPSS‐R lower‐risk category (low‐very low vs intermediate‐very high, *P* \< .001) were all significant positive prognostic factors for OS. Median OS was significantly shorter for RAEB and RCMD cases (31 and 40 months, respectively) compared to RA and RARS cases (83 and 95 months, respectively, *P* = .002) (Table [S3](#cam42638-sup-0001){ref-type="supplementary-material"}). Patients achieving HI‐E had a longer OS (median OS: 86.2 vs 52.3 m, *P* = .028; Figure [2](#cam42638-fig-0002){ref-type="fig"}A). Figure [2](#cam42638-fig-0002){ref-type="fig"}B shows the OS in the two cohorts of patients according to HI‐E achievement. Since median survival was not reached in some groups, mean values are reported. No significant differences were observed according to rhEPO dose within the different subgroups (no responders: 75.1 months for SD and 67.4 months for HD, *P* = .63; responders: 78.1 months for SD and 91.4 months for HD, *P* = .27).

![Overall survival of patients according to erythroid response in both cohorts (A) and within different subgroups according to different rhEPO doses (B)](CAM4-8-7567-g002){#cam42638-fig-0002}

A multivariate analysis carried out adjusting for gender, age, rhEPO dose, transfusion dependency, ferritin, marrow blasts, WHO classification, and IPSS‐R score, OS was confirmed to be better for younger patients (HR = 0.62, 95% CI 0.52‐0.75, *P* \< .001) for those with lower IPSS‐R score (HR = 0.64, 95% CI 0.51‐0.82, *P* \< .001) and with transfusion independence (HR = 0.78, 95% CI 0.65‐0.94, *P* = .010) (Table [S4](#cam42638-sup-0001){ref-type="supplementary-material"}).

3.5. Impact of clinical characteristics on response to HD or SD ESA doses {#cam42638-sec-0014}
-------------------------------------------------------------------------

Within the HD and SD cohorts, we also investigated whether a higher HI‐E rate or a longer OS could be associated with specific clinical characteristics. Figure [3](#cam42638-fig-0003){ref-type="fig"}A shows the subgroup analyses regarding HI‐E and Figure [3](#cam42638-fig-0003){ref-type="fig"}B the analysis regarding OS. Higher HI‐E rate was observed in HD cohort compared with SD cohort in both transfusion‐dependent patients and higher IPSS‐R risk categories (*P* = .001 and *P* = .007 respectively), but no significant impact on OS was detected in these subgroups of prognostically more severe patients.

![Forest plot of subgroup analyses of erythroid response (A) and overall survival (B) comparing rhEPO high dose (HD) vs rhEPO standard dose (SD) within the strata of each relevant clinical factor](CAM4-8-7567-g003){#cam42638-fig-0003}

3.6. Progression to AML according to ESA doses {#cam42638-sec-0015}
----------------------------------------------

Overall, 38 patients (12.2%) (14.4% in SD and 7.7% in HD group respectively), progressed to AML. Progression to AML was significantly higher among patients with transfusion dependency (19.5% vs 9.3% in nondependent patients, *P* = .02), with higher marrow blast count (27.6% for ≥5% vs 8.6% for \<5, *P* \< .001), without HI‐E (18.9% vs 6.1% for responders, *P* = .001), and with higher IPSS‐R risk categories (27.0% for intermediate‐very high‐risk and 6.3% for low‐very low‐risk scores, *P* = .001). Higher progression to AML, although not significant, was also observed among younger patients (15.1% ≤75 year vs 8.6% for \>75 years, *P* = .085). A multivariate analysis adjusted for age, rhEPO dose, transfusion dependency, marrow blast percentage, WHO categories and IPSS‐R score, a higher blast percentage (\>5%: OR = 1.91, 95% CI 1.01‐3.60, *P* = .047) and IPSS‐R score (intermediate or higher: OR = 1.85, 95% CI 1.16‐2.95, *P* = .010) were predictive of progression to AML. rhEPO doses were not associated with AML progression (HD: OR = 0.71, 95% CI 0.46‐1.10, *P* = .13).

When restricting the analysis to the 274 patients who did not progress to AML, multivariate analysis confirmed that rhEPO doses were not associated with HI‐E (OR = 0.90, 95% CI 0.69‐1.17, *P* = .44). Transfusion dependence was associated with the lack of response (no vs yes: OR = 1.54, 95% CI 1.15‐2.07, *P* = .004). Endogenous serum EPO levels (≤200 U/L vs \>200 U/L: OR = 1.33, 95% CI 0.96‐1.85, *P* = .083) were weakly associated with HI‐E as well as IPSS‐R risk categories (very low‐low vs intermediate or higher: OR = 1.41, 95% CI 0.95‐2.09, *P* = .083).

3.7. Random intercept logistic regression analysis among propensity‐matched patients {#cam42638-sec-0016}
------------------------------------------------------------------------------------

The random intercept logistic regression modeling taking into account therapy and gender confirmed that rhEPO dose was not a predictive factor for response (HD vs SD: OR = 0.74, 95% CI 0.45‐1.22) (Table [3](#cam42638-tbl-0003){ref-type="table"}, model 1). No statistically significant association was also seen between rhEPO doses and progression to AML (HD vs SD: OR = 0.48, 95% CI 0.20‐1.11) (Table [3](#cam42638-tbl-0003){ref-type="table"}, model 3). Higher‐dose rhEPO treatment was not a positive prognostic factor for OS (HR = 0.82, 95% CI 0.55‐1.21) (Table [4](#cam42638-tbl-0004){ref-type="table"}, model 1). Similar results were obtained when the analysis was restricted to patients not progressing to AML, with an OR of 0.66 (95% CI 0.40‐1.10) for HI‐E (Table [3](#cam42638-tbl-0003){ref-type="table"}, model 2) and a HR of 0.92 (95% CI 0.59‐1.46) for OS (Table [4](#cam42638-tbl-0004){ref-type="table"}, model 2).

###### 

Effect of treatment doses and gender on erythroid response rates and progression to acute myeloid leukemia estimated through the random intercept logistic regression modeling, after matching patients on propensity score derived from age, endogenous EPO, transfusion dependency, Hb, ferritin, and IPSS score

  Variable                              Model 1 (n = 312)   Model 2 (n = 274)   Model 3 (n = 312)                             
  ------------------------------------- ------------------- ------------------- ------------------- ------------------ ------ ------------------
  Treatment: higher vs standard doses   0.74                0.45‐1.22 (.235)    0.66                0.40‐1.10 (.114)   0.48   0.20‐1.11 (.086)
  Gender: female vs male                0.92                0.57‐1.50 (.737)    0.89                0.54‐1.47 (.646)   0.89   0.43‐1.84 (.753)

Model 1: erythroid response as outcome, all patients; Model 2: erythroid response as outcome, leukemia‐free patients; Model 3: leukemia as outcome.

Abbreviations: 95% CL: 95% confidence limits for OR; OR: odds ratio; *P*‐value: significance level of the likelihood ratio test.
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###### 

Effect of treatment doses and gender on overall survival estimated through the random intercept Cox regression modeling, after matching patients on propensity score derived from age, endogenous EPO, transfusion dependency, Hb, ferritin, and IPSS score

  Variable                              Model 1 (n = 312)   Model 2 (n = 274)          
  ------------------------------------- ------------------- ------------------- ------ ------------------
  Treatment: higher vs standard doses   0.82                0.55‐1.21 (.318)    0.92   0.59‐1.46 (.747)
  Gender: female vs male                0.51                0.34‐0.78 (.002)    0.50   0.31‐0.82 (.006)

Model 1: all patients; Model 2: leukemia‐free patients.

Abbreviations: 95% CL, 95% confidence limits for HR; HR, hazard ratio; *P*‐value, significance level of the likelihood ratio test.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42638-sec-0017}
=============

Our study shows that anemic MDS patients treated with different rhEPO doses (either SD or HD) achieve similar HI‐E rates, provided that they have similar clinical characteristics influencing the eligibility for treatment with ESAs.

These results apparently contrast with previous studies on MDS anemic patients indicating a higher response rate to ESAs, and in particular to rhEPO, when HD are employed[13](#cam42638-bib-0013){ref-type="ref"}, [14](#cam42638-bib-0014){ref-type="ref"} compared to SD.[10](#cam42638-bib-0010){ref-type="ref"} These latter poor results were mostly obtained in clinical studies performed in the early 90s using different but usually relatively low doses of rhEPO in the various subsets of MDS patients; in fact, in that early period trials actually enrolled a relevant proportion of patients with more advanced MDS, including subjects with RAEB and/or patients with a greater transfusional need. Most of these patients would be in present days classified as "high‐risk," for whom to date treatment with ESAs is not generally considered an optimal choice.

Two meta‐analyses comparing studies performed in quite a long time lapse and with different dosing schedules in possibly heterogeneous groups of MDS patients indicated a possible superiority of HD of rhEPO vs SD. Data from 30 selected studies on MDS patients treated with ESAs at different dosing showed that HD of both rhEPO and darbepoetin induced higher HI‐E in lower‐risk MDS.[21](#cam42638-bib-0021){ref-type="ref"} However, in a subsequent meta‐analysis focused on rhEPO, among MDS patients treated with SD a significantly higher number of cases had marrow blasts \>5% than cases treated with HD and SD patients treated had significantly higher endogenous serum EPO levels.[22](#cam42638-bib-0022){ref-type="ref"} Both these factors are clearly related to a poor response to rhEPO[9](#cam42638-bib-0009){ref-type="ref"} and possibly influenced the clinical outcome. Strictly selected MDS lower‐risk patients treated with SD had response rates equivalent to those observed with HD.[23](#cam42638-bib-0023){ref-type="ref"}, [24](#cam42638-bib-0024){ref-type="ref"} The recent randomized trial comparing safety and efficacy of rhEPO with placebo in low‐risk MDS patients used weight‐adjusted doses of rhEPO, substantially equivalent to SD.[25](#cam42638-bib-0025){ref-type="ref"}

Erythroid response to ESAs is determined in fact by several predictive factors, and different clinical scores have been proposed during the years. Beyond the Nordic score,[17](#cam42638-bib-0017){ref-type="ref"} when only "low‐risk" MDS anemic patients with a blast count of less than 10% and with a low transfusion burden were treated with rhEPO,[26](#cam42638-bib-0026){ref-type="ref"} response rate was actually more than doubled comparing with previous studies.[10](#cam42638-bib-0010){ref-type="ref"} An IPSS‐R‐based predictive system has been more recently proposed considering also serum EPO and ferritin concentrations.[18](#cam42638-bib-0018){ref-type="ref"} It significantly predicted HI‐E after ESAs and it was recently already validated by a larger study.[27](#cam42638-bib-0027){ref-type="ref"} In the present study, we compared two cohorts of patients according to their eligibility to be treated with rhEPO applying a propensity score based on the clinical parameters influencing treatment choice. When the impact of different rhEPO doses was evaluated within such two homogenous cohorts the differences in response rates did not statistically differ. Transfusion‐dependent MDS patients and/or those with a higher IPSS‐R risk score in any case benefit more from HD than from SD, in terms of achievement of HI‐E. In these subsets of MDS patients, it would therefore be advisable to start treatment with HD ESAs, if other therapeutic options (ie, as example, hypomethylating agents) are not suitable or possible.

Our results are consistent with previous ones indicating longer OS in MDS patients who achieve HI‐E, at whichever rhEPO doses used.[8](#cam42638-bib-0008){ref-type="ref"}, [9](#cam42638-bib-0009){ref-type="ref"} We recently demonstrated that a trend for survival advantage is present for MDS patients with isolated erythroid dysplasia (RA/RARS/del5q) receiving ESAs for severe‐moderate anemia (8‐10 g/dL).[28](#cam42638-bib-0028){ref-type="ref"}

Treatment with rhEPO---irrespectively of the doses used---do not have significant impact on progression to AML, which was higher among MDS patients not responding to rhEPO, transfusion‐dependent patients and with higher IPSS‐R risk scores, confirming previous results.[29](#cam42638-bib-0029){ref-type="ref"}, [30](#cam42638-bib-0030){ref-type="ref"}

In conclusion, although with the limits of a retrospective analysis and a relatively limited number of cases, our study indicates that the SD of rhEPO is as effective as HD in improving anemia in MDS patients stratified according to the propensity score of treatment, with the exception of transfusion‐dependent patients and with higher IPSS‐R risk scores. Moreover, different doses have the same effects on OS and risk of AML transformation. Our observations may lead to a wiser use of SD of rhEPO, reserving HD to the above indicated subcategories of MDS patients, limiting the economic impact of the treatment. It has been shown that early use of ESAs can significantly delay the onset of a transfusion need in lower‐risk MDS patients, and is associated with a reduced chance of death in responding patients.[31](#cam42638-bib-0031){ref-type="ref"} This further supports the relevance of our analysis in view of increased appropriateness in early therapy with ESAs.
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